Patents by Inventor Tsutomu Arakawa
Tsutomu Arakawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11001627Abstract: A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.Type: GrantFiled: September 29, 2017Date of Patent: May 11, 2021Assignee: Coherus BioSciences, Inc.Inventors: Tsutomu Arakawa, Douglas Farrar
-
Patent number: 10954295Abstract: A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.Type: GrantFiled: June 17, 2019Date of Patent: March 23, 2021Assignee: Coherus BioSciences, Inc.Inventors: Tsutomu Arakawa, Douglas Farrar
-
Patent number: 10954294Abstract: A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.Type: GrantFiled: June 17, 2019Date of Patent: March 23, 2021Assignee: Coherus BioSciences, Inc.Inventors: Tsutomu Arakawa, Douglas Farrar
-
Patent number: 10954293Abstract: A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.Type: GrantFiled: June 17, 2019Date of Patent: March 23, 2021Assignee: Coherus BioSciences, Inc.Inventors: Tsutomu Arakawa, Douglas Farrar
-
Patent number: 10947306Abstract: A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.Type: GrantFiled: June 17, 2019Date of Patent: March 16, 2021Assignee: Coherus BioSciences, Inc.Inventors: Tsutomu Arakawa, Douglas Farrar
-
Publication number: 20190330325Abstract: A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.Type: ApplicationFiled: June 17, 2019Publication date: October 31, 2019Applicant: COHERUS BIOSCIENCES, INC.Inventors: Tsutomu ARAKAWA, Douglas FARRAR
-
Publication number: 20190300601Abstract: A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.Type: ApplicationFiled: June 17, 2019Publication date: October 3, 2019Applicant: COHERUS BIOSCIENCES, INC.Inventors: Tsutomu ARAKAWA, Douglas FARRAR
-
Publication number: 20190300600Abstract: A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.Type: ApplicationFiled: June 17, 2019Publication date: October 3, 2019Applicant: COHERUS BIOSCIENCES, INC.Inventors: Tsutomu ARAKAWA, Douglas FARRAR
-
Publication number: 20190300602Abstract: A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.Type: ApplicationFiled: June 17, 2019Publication date: October 3, 2019Applicant: COHERUS BIOSCIENCES, INC.Inventors: Tsutomu ARAKAWA, Douglas FARRAR
-
Publication number: 20180037642Abstract: A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.Type: ApplicationFiled: September 29, 2017Publication date: February 8, 2018Inventors: Tsutomu Arakawa, Douglas Farrar
-
Patent number: 9872499Abstract: The invention provides a virus-inactivating composition with pH of 3.8 to 5.5, containing (A) 0.02 to 0.3 M arginine and (B) a component such as 0.01 to 10 mM flavonoid, polyphenol, or ascorbic acid derivative, 0.005 to 5 mass % of an arginine derivative, and 0.1 to 2.5 mass % of an extract solution of natural product.Type: GrantFiled: August 22, 2012Date of Patent: January 23, 2018Assignee: AJINOMOTO CO., INC.Inventors: Daisuke Ejima, Haruna Sato, Hajime Koyama, Tsutomu Arakawa
-
Publication number: 20170143834Abstract: Pharmaceutical compositions, in particular, compositions comprising growth hormone (GH) and insulin-like growth factor (IGF-1) which are stable at a desirable pH without aggregation formation, and processes for preparing such compositions.Type: ApplicationFiled: September 30, 2016Publication date: May 25, 2017Inventors: Enona GOPINATH, Susan PARK, Tsutomu ARAKAWA, Joël RICHARD, Fabio FAIS
-
Patent number: 9462810Abstract: The present invention provides a method for conveniently producing a protein formulation in which viruses are inactivated, without impairing the quality of the obtained protein formulation, characterized by including the step of exposing the protein formulation contaminated with the viruses to a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5. The present invention also provides a virus inactivation method characterized by including the step of contacting a virus-containing object with a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5.Type: GrantFiled: December 17, 2013Date of Patent: October 11, 2016Assignee: AJINOMOTO CO., INC.Inventors: Hajime Koyama, Tsutomu Arakawa, Daisuke Ejima
-
Publication number: 20140107207Abstract: The present invention provides a method for conveniently producing a protein formulation in which viruses are inactivated, without impairing the quality of the obtained protein formulation, characterized by including the step of exposing the protein formulation contaminated with the viruses to a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5. The present invention also provides a virus inactivation method characterized by including the step of contacting a virus-containing object with a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5.Type: ApplicationFiled: December 17, 2013Publication date: April 17, 2014Applicant: AJINOMOTO CO., INC.Inventors: Hajime Koyama, Tsutomu Arakawa, Daisuke Ejima
-
Publication number: 20140072560Abstract: A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.Type: ApplicationFiled: September 11, 2013Publication date: March 13, 2014Applicant: COHERUS BIOSCIENCES, INC.Inventors: Tsutomu Arakawa, Douglas Farrar
-
Patent number: 8669045Abstract: The present invention provides a method for conveniently producing a protein formulation in which viruses are inactivated, without impairing the quality of the obtained protein formulation, characterized by including the step of exposing the protein formulation contaminated with the viruses to a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5. The present invention also provides a virus inactivation method characterized by including the step of contacting a virus-containing object with a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5.Type: GrantFiled: February 13, 2008Date of Patent: March 11, 2014Assignee: Ajinomoto Co., Inc.Inventors: Hajime Koyama, Tsutomu Arakawa, Daisuke Ejima
-
Patent number: 8632778Abstract: The present invention provides stabilized preparations containing an antibody in a glycine buffer and/or a histidine buffer and also provides processes for preparing a protein-containing stabilized preparation, comprising adjusting the pH with a basic amino acid or a basic amino acid derivative or a salt thereof.Type: GrantFiled: August 13, 2001Date of Patent: January 21, 2014Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masaya Kakuta, Tadao Yamazaki, Akira Hayasaka, Yoshiki Hayashi, Tsutomu Arakawa
-
Patent number: 8470328Abstract: The present invention provides a method of purifying an antibody by protein A affinity chromatography. More specifically, the present invention provides a technique relating to an elution buffer solution which provides a good antibody recovery rate without denaturation.Type: GrantFiled: June 26, 2012Date of Patent: June 25, 2013Assignee: Ajinomoto Co., Inc.Inventors: Ryosuke Yumioka, Daisuke Ejima, Tsutomu Arakawa
-
Patent number: 8444990Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.Type: GrantFiled: October 8, 2010Date of Patent: May 21, 2013Assignee: Amgen Inc.Inventors: Tsutomu Arakawa, Yoshiko Kita
-
Patent number: 8435527Abstract: The present invention provides a method of purifying an antibody by protein A affinity chromatography. More specifically, the present invention provides a technique relating to an elution buffer solution which provides a good antibody recovery rate without denaturation.Type: GrantFiled: November 29, 2011Date of Patent: May 7, 2013Assignee: Ajinomoto Co., Inc.Inventors: Ryosuke Yumioka, Daisuke Ejima, Tsutomu Arakawa